Recent advances in PLGA particulate systems for drug delivery

Journal of Pharmaceutical Investigation

Volumn 42, Issue 3, 2012, Pages 155-163

  Choi, Jin Seok ^a   Seo, Kyuhwa ^a   Yoo, Jin Wook ^a  

^a Chosun University   (South Korea)

Author keywords

Biocompatible drug carrier; Drug delivery; Microparticles; Nanoparticles; PLGA

Indexed keywords

AMPHOTERICIN B; ARGINYLGLYCYLASPARTIC ACID; CISPLATIN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLURBIPROFEN; INSULIN; NANOPARTICLE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLEATE SODIUM; PACLITAXEL; POLYGLACTIN; RIFAMPICIN; SMALL INTERFERING RNA; SPARFLOXACIN; TUMOR NECROSIS FACTOR; VANCOMYCIN;

BIOCOMPATIBILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; GENE DELIVERY SYSTEM; HUMAN; IC 50; INTRAOCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; NEOPLASM; NONHUMAN; ORAL DELIVERY; PRIORITY JOURNAL; PULMONARY DELIVERY; REVIEW;

EID: 84870313070     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-012-0024-5     Document Type: Review

References (80)

1. Acharya S, Sahoo SK (2011) PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63: 170-183.
2. Acharya S, Dilnawaz F, Sahoo SK (2009) Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30: 5737-5750.
3. Agnihotri SM, Vavia PR (2009) Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomed Nanotechnol Biol Med 5: 90-95.
4. Aguiar MMG, Rodrigues JM, Silva Cunha A (2004) Encapsulation of insulin-cyclodextrin complex in PLGA microspheres: a new approach for prolonged pulmonary insulin delivery. J Microencapsul 21: 553-564.
5. Ali Y, Lehmussaari K (2006) Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 58: 1258-1268.
6. Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB (2009) Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B 72: 48-56.
7. Aravind A, Varghese S, Veeranarayanan S, Mathew A, Nagaoka Y, Iwai S, Fukuda T, Hasumura T, Yoshida Y, Maekawa T, Kumar D (2012) Aptamer-labeled PLGA nanoparticles for targeting cancer cells. Cancer Nanotechnol. doi: 10. 1007/s12645-011-0024-6.
8. Arruebo M, Valladares M, Gonzalez-Fernandez A (2009) Antibody-conjugated nanoparticles for biomedical applications. J Nanomater 2009: 1-24.
9. Badawi A, El-Laithy H, El Qidra R, El Mofty H, El dally M (2008) Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharmacal Res 31: 1040-1049.
10. Balamurugan S, Obubuafo A, Soper S, Spivak D (2008) Surface immobilization methods for aptamer diagnostic applications. Anal Bioanal Chem 390: 1009-1021.
11. Beck-Broichsitter M, Merkel OM, Kissel T (2012) Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release. doi: 10. 1016/j. jconrel. 2011. 12. 004.
12. Bhavane R, Karathanasis E, Annapragada AV (2003) Agglomerated vesicle technology: a new class of particles for controlled and modulated pulmonary drug delivery. J Control Release 93: 15-28.
13. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G (2004) PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm 58: 1-6.
14. Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Franken KLMC, Friggen AH, Junginger HE, Borchard G, Klein MR, Ottenhoff THM (2009) Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27: 4010-4017.
15. Blum J, Weller C, Booth C, Babar I, Liang X, Slack F, Saltzman W (2011) Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles. Drug Deliv Transl Res 1: 383-394.
16. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651.
17. Brooks P, Clark R, Cheresh D (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571.
18. Carino GP, Jacob JS, Mathiowitz E (2000) Nanosphere based oral insulin delivery. J Control Release 65: 261-269.
19. Champion JA, Katare YK, Mitragotri S (2007) Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 121: 3-9.
20. Chang E, McClellan AJ, Farley WJ, Li D-Q, Pflugfelder SC, De Paiva CS (2011) Biodegradable PLGA-based drug delivery systems for modulating ocular surface disease under experimental murine dry eye. J Clin Exp Ophthalmol 2: 1-6.
21. Coowanitwong I, Arya V, Kulvanich P, Hochhaus G (2008) Slow release formulations of inhaled rifampin. AAPS J 10: 342-348.
22. Cu Y, Booth CJ, Saltzman WM (2011) In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release 156: 258-264.
23. Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP (1990) Nanocapsules as carriers for oral peptide delivery. J Control Release 13: 233-239.
24. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, Jérôme C, Marchand-Brynaert J, Feron O, Préat V (2009) Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release 140: 166-173.
25. De Stefano D, Ungaro F, Giovino C, Polimeno A, Quaglia F, Carnuccio R (2011) Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-κB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells. J Gene Med 13: 200-208.
26. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116: 1-27.
27. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105: 17356-17361.
28. Di Toro R, Betti V, Spampinato S (2004) Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly(dl-lactide-co-glycolide) copolymers. Eur J Pharm Sci 21: 161-169.
29. Dong Y, Feng S-S (2005) Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26: 6068-6076.
30. Edwards DA, Ben-Jebria A, Langer R (1998) Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85: 379-385.
31. Emami J, Hamishehkar H, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, Mirzadeh H, Fakhari A, Nokhodchi A (2009) Particle size design of PLGA microspheres for potential pulmonary drug delivery using response surface methodology. J Microencapsul 26: 1-8.
32. Ensign LM, Cone R, Hanes J (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64: 557-570.
33. Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R (1998) Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1, 2-dipalmitoylphosphatidylcholine. J Control Release 51: 143-152.
34. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P (2004) PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm 57: 207-212.
35. Gref R, Minamitake Y, Peracchia M, Trubetskoy V, Torchilin V, Langer R (1994) Biodegradable long-circulating polymeric nanospheres. Science 263: 1600-1603.
36. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G (2010) Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomed Nanotechnol Biol Med 6: 324-333.
37. Ham A, Cost M, Sassi A, Dezzutti C, Rohan L (2009) Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 26: 502-511.
38. Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Hassanzadeh K, Mahdavi H, Koohsoltani M, Nokhodchi A (2010) Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm Drug Dispos 31: 189-201.
39. Hara K, Tsujimoto H, Tsukada Y, Huang CC, Kawashima Y, Tsutsumi M (2008) Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 356: 267-273.
40. Italia J, Yahya M, Singh D, Ravi Kumar M (2009) Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone®. Pharm Res 26: 1324-1331.
41. Jain GK, Pathan SA, Akhter S, Jayabalan N, Talegaonkar S, Khar RK, Ahmad FJ (2011) Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery system. Colloids Surf B 82: 397-403.
42. Jensen DK, Jensen LB, Koocheki S, Bengtson L, Cun D, Nielsen HM, Foged C (2012) Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 157: 141-148.
43. Kalaria D, Sharma G, Beniwal V, Ravi Kumar M (2009) Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 26: 492-501.
44. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T (1999) Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 62: 279-287.
45. Lai SK, Wang Y-Y, Hida K, Cone R, Hanes J (2010) Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci USA 107: 598-603.
46. Lee CH, Moturi V, Lee Y (2009) Thixotropic property in pharmaceutical formulations. J Control Release 136: 88-98.
47. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26: 442-449.
48. Luo G, Yu X, Jin C, Yang F, Fu D, Long J, Xu J, Zhan C, Lu W (2010) LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 385: 150-156.
49. McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, Scott CJ (2008) Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem 19: 1561-1569.
50. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV (2007) Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 119: 77-85.
51. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK (2009) Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 136: 2-13.
52. Panyam J, Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V (2002) Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16: 1217-1226.
53. Patil Y, Sadhukha T, Ma L, Panyam J (2009a) Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136: 21-29.
54. Patil YB, Toti US, Khdair A, Ma L, Panyam J (2009b) Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 30: 859-866.
55. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J (2010) The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31: 358-365.
56. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760.
57. Pérez C, Griebenow K (2003) Effect of salts on lysozyme stability at the water-oil interface and upon encapsulation in poly(lactic-co-glycolic) acid microspheres. Biotechnol Bioeng 82: 825-832.
58. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA (2005) Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24: 47-69.
59. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2: 373-383.
60. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR (2009) Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37: 223-230.
61. Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, Hou SX, Xiong SJ, Lei XJ, Wei YQ (2009) Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37: 300-305.
62. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ (2001) Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 18: 1315-1319.
63. Sun S, Cui F, Kawashima Y, Liang N, Zhang L, Shi K, Yu Y (2008) A novel insulin-sodium oleate complex for oral administration: preparation, characterization and in vivo evaluation. J Drug Deliv Sci Technol 18: 239-243.
64. Sun S, Liang N, Piao H, Yamamoto H, Kawashima Y, Cui F (2010) Insulin-S. O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. J Microencapsul 27: 471-478.
65. Sung JC, Pulliam BL, Edwards DA (2007) Nanoparticles for drug delivery to the lungs. Trends Biotechnol 25: 563-570.
66. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI (2006) Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 28: 423-432.
67. Ungaro F, di Villa d'Emmanuele, Bianca R, Giovino C, Miro A, Sorrentino R, Quaglia F, LaRotonda MI (2009) Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 135: 25-34.
68. Ungaro F, d'Angelo I, Coletta C, d'Emmanuele di Villa Bianca R, Bianca R, Sorrentino R, Perfetto B, Tufano MA, Miro A, La Rotonda MI, Quaglia F (2012) Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 157: 149-159.
69. Vega E, Gamisans F, García ML, Chauvet A, Lacoulonche F, Egea MA (2008) PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J Pharm Sci 97: 5306-5317.
70. Whaley KJ, Hanes J, Shattock R, Cone RA, Friend DR (2010) Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res 88(Supplement): S55-S66.
71. Wu X (1995) Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Wise DL, Trantolo DJ, Altobelli DE, Yaszemski MJ, Gresser JD, Schwartz ER (eds) Encyclopedic handbook of biomaterials and bioengineering. Part A. Materials, vol 2. Marcel Dekker, New York, pp 1015-1054.
72. Wu ZM, Zhou L, Guo XD, Jiang W, Ling L, Qian Y, Luo KQ, Zhang LJ (2012) HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int J Pharm 425: 1-8.
73. Yoo J-W, Mitragotri S (2010) Polymer particles that switch shape in response to a stimulus. Proc Nat Acad Sci USA 107: 11205-11210.
74. Yoo J-W, Choe E-S, Ahn S-M, Lee CH (2010a) Pharmacological activity and protein phosphorylation caused by nitric oxide-releasing microparticles. Biomaterials 31: 552-558.
75. Yoo J-W, Lee J-S, Lee CH (2010b) Characterization of nitric oxide-releasing microparticles for the mucosal delivery. J Biomed Mater Res A 92: 1233-1243.
76. Yoo J-W, Giri N, Lee CH (2011a) pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharm 403: 262-267.
77. Yoo J-W, Irvine DJ, Discher DE, Mitragotri S (2011b) Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 10: 521-535.
78. Zhang S, Zhao B, Jiang H, Wang B, Ma B (2007) Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release 123: 1-10.
79. Zhang T, Sturgis TF, Youan B-BC (2011) pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm 79: 526-536.
80. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM (2012) Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33: 583-591.